Acquisitions in Zurich, Switzerland

Showing 3 transactions.

All acquisitions in Switzerland
  • Advent International Completes Acquisition of u-blox
    November 26, 2025
    Buyer
    Advent International, L.P., ZI Zenith S.à r.l.
    Target
    u-blox Holding AG (u-blox)
    Seller
    u-blox shareholders
    Industry
    Manufacturing
    Location
    Zurich, Switzerland
    Type
    Buyout

    ZI Zenith S.à r.l., an indirect subsidiary of funds managed and/or advised by Advent International, completed its public tender offer to acquire u-blox Holding AG, a Swiss provider of positioning and wireless communication technologies. With regulatory approvals secured and conditions satisfied, Advent is settling the offer at CHF 135 per share and will own more than 98% of u-blox, with a statutory squeeze-out and delisting to follow.

  • Swiss Post to Acquire Open Systems from EQT
    September 18, 2024
    Buyer
    Swiss Post
    Target
    Open Systems
    Seller
    EQT Private Equity, EQT Mid Market Europe fund, co-shareholders of Open Systems
    Industry
    Cybersecurity
    Location
    Zurich, Switzerland
    Type
    Buyout

    EQT Private Equity and its co-shareholders have agreed to sell Open Systems, a Zurich-headquartered provider of cloud-based network and cybersecurity (SASE) solutions, to Swiss Post. The deal is expected to close in Q4 2024 subject to customary regulatory approvals, and Open Systems will continue under CEO Daniel Neuhaus within Swiss Post’s Communication Services business.

  • Atlas Antibodies Acquires evitria AG
    July 28, 2021
    Buyer
    Atlas Antibodies, Patricia Industries (Investor AB)
    Target
    evitria AG
    Seller
    Afinum, SHS
    Industry
    Biotechnology
    Location
    Zurich, Switzerland
    Type
    Buyout

    Atlas Antibodies, a Patricia Industries (Investor AB) holding, agreed to acquire evitria AG, a Swiss leader in custom recombinant antibody expression in CHO cells. The deal combines Atlas Antibodies’ validated research antibody portfolio with evitria’s antibody expression services to form an antibody-focused platform serving biopharma and academic customers. Sellers include Afinum and co-investor SHS, with closing expected in Q3 2021.